In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
CrowdStrike's 2025 data shows attackers breach AI systems in 51 seconds. Field CISOs reveal how inference security platforms ...
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback